TransCode Therapeutics is a biotechnology business based in the US. TransCode Therapeutics shares (RNAZ) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.70 – an increase of 29.51% over the previous week. TransCode Therapeutics employs 10 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.70 |
|---|---|
| 52-week range | $0.22 - $21.20 |
| 50-day moving average | $0.33 |
| 200-day moving average | $1.19 |
| Wall St. target price | $120.00 |
| PE ratio | 0.002 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $268.14 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.7 from 2024-10-11
| 1 week (2024-10-08) | 45.14% |
|---|---|
| 1 month (2024-09-13) | 170.17% |
| 3 months (2024-07-15) | -22.25% |
| 6 months (2024-04-15) | 30.52% |
| 1 year (2023-10-13) | 62.11% |
|---|---|
| 2 years (2022-10-14) | -36.99% |
| 3 years (2021-10-15) | 3.22 |
| 5 years (2019-10-11) | N/A |
Valuing TransCode Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of TransCode Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
TransCode Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, TransCode Therapeutics shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, TransCode Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -207.95% |
| Return on equity TTM | -1048.7% |
| Profit margin | 0% |
| Book value | $0.18 |
| Market Capitalization | $10.2 million |
TTM: trailing 12 months
TransCode Therapeutics's shares were split on a 1:40 basis on 15 January 2024. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your TransCode Therapeutics shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for TransCode Therapeutics shares which in turn could have impacted TransCode Therapeutics's share price.
Over the last 12 months, TransCode Therapeutics's shares have ranged in value from as little as $0.216 up to $21.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TransCode Therapeutics's is 0.631. This would suggest that TransCode Therapeutics's shares are less volatile than average (for this exchange).
To put TransCode Therapeutics's beta into context you can compare it against those of similar companies.
TransCode Therapeutics, Inc. , a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.